Preparation Begins animal efficacy testing for leishmaniasis treatmentUpstream Biosciences Inc.

Preparation Begins animal efficacy testing for leishmaniasis treatmentUpstream Biosciences Inc. announced that it work with the Makerere University in Kampala, Uganda, to evaluate the efficacy in animals of more than 20 proprietary drug candidates as potential treatments for leishmaniasis in humans. Resistance has greatly reduced the effectiveness of existing Leishmaniasis treatments.

In addition to these growing markets, we were able earn our drugs via the U.S. FDA priority voucher program money. .. Bellenson said Upstream has demonstrated in vitro efficacy and in vivo safety for potential treatments for leishmaniasis, malaria and Trypanaosomiasis.Leishmaniasis, Kampala, and malaria parasites have developed resistance through related to available treatments cause. Leishmaniasis affecting millions of people in Africa, India and the Middle East. Estimated 60 million people and 50 million cattle and other animals in sub-Saharan Africa are at risk. With African sleeping sickness According to the World Health Organization, about 40 percent of the global population is at risk of malaria. These diseases are in the U.S. Food and Drug Administration proposed priority review voucher program designed financial incentives for companies financial incentives for companies offer treatments are included.Expected, all wounded the heart revealed shoot several spontaneous arrhythmia, more in the time of infarct and transplant. Importantly, was no significant difference in frequency by either spontaneous or induced arrhythmias between the beneficiaries and vehicle GRNCM1 that. Lack of arrhythmic potential of the GRNCM1 in this attitude on myocardial infarction 1,2 million people current performs GRNCM1 in a swine flu infarction models further evaluation is preclinical safety and efficacy GRNCM1 in a wider an animal model with a cardiovascular system from similar size and structure to humans.

Geron Corporation announced today point positive preclinical trial data in that GRNCM1, Geron cardiomyocyte products on human embryonic stem derived any cardiac arrhythmia caused after transplantation in one model of chronic damage of heart designed in order to test this potential safety concern. GRNCM1 for treatment of for the treatment of heart failure.